Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF

AIMS: Iron deficiency is common in patients with heart failure (HF). In AFFIRM‐AHF, ferric carboxymaltose (FCM) reduced the risk of hospitalisations for HF (HHF) and improved quality of life vs. placebo in iron‐deficient patients with a recent episode of acute HF. The objective of this study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: McEwan, Phil, Ponikowski, Piotr, Davis, Jason A., Rosano, Giuseppe, Coats, Andrew J.S., Dorigotti, Fabio, O'Sullivan, Donal, Ramirez de Arellano, Antonio, Jankowska, Ewa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2021
Materias:
Focused Issue on Comorbidities
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596684/
https://www.ncbi.nlm.nih.gov/pubmed/34191394
http://dx.doi.org/10.1002/ejhf.2270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596684/
https://www.ncbi.nlm.nih.gov/pubmed/34191394
http://dx.doi.org/10.1002/ejhf.2270

Ejemplares similares